News | June 06, 2022
Proxygen and Merck collaborates to develop molecular glue degraders
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
The rally attracted around 250 riders, including professionals and amateurs.
The company has posted net loss of Rs. 67.65 crores for the Financial Year ended March 31, 2022
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Susanne Kaestner joins the company as Senior Vice President, Quality and member of the Executive Team, and Dr. Thea Boehm as Vice President, Business Development.
A research group led by Ben-Gurion University of the Negev managed to produce an innovative microchip for creating sperm in a culture by using a microfluidic system.
To address the preventive & primary healthcare delivery gaps in India
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas.
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
Subscribe To Our Newsletter & Stay Updated
